103 · L1 IP Fundamentals

The 5 main IP rights

Patentability

• Novel (new), Useful, Non-obvious/inventive, Described & enabled
• A patent gives the right to exclude others — NOT the right to practice. Rights are territorial.
• Your own public disclosure (paper, pitch, website) destroys novelty!

The full IP toolkit — beyond the "big 5"

The L1 "right kind of IP" map lists more than five rights. A biotech must know the whole toolkit because different assets need different protection:

Trademark — definition, protection & infringement

A trademark is generally a word, phrase, symbol, or design, or a combination thereof, that identifies and distinguishes the source of the goods of one party from those of others. A service mark is the same, but identifies a service rather than goods. The right gives the owner the exclusive use of the mark for specific goods / services.

What a trademark actually protects is the mental association in the consumer's mind between a product and its source. To be protectable a mark must be:

• Inherently distinctive
• Connected with the goods or services
• Used in commerce (or intent-to-use)

Trademark distinctiveness — the spectrum and what each category means

Strength runs along a fixed scale: Generic (no protection) → Descriptive (needs secondary meaning) → Suggestive → Arbitrary → Fanciful (strongest). A word can slide down that scale — "Aspirin" became generic and lost protection — while invented words stay at the top. The table below gives the definition and an example for each category.

Copyright — scope & exclusive rights

Copyright protects the expression of an idea (not the idea itself), fixed in a tangible medium. It typically protects literary work, art, images, movies, music, computer software and code.

The owner gets the exclusive right to copy, distribute, adapt, display and perform a creative work. Term: Life + 70 years.

Trade secret & design — the "quiet" IP

• Trade secret: protects secret information; protection lasts forever as long as active measures (NDAs) are taken. The owner has the exclusive right to use the secret, provided it is not discovered by others.
• Design: protects a product's visual / ornamental (non-functional) appearance. Owner has the exclusive right to use the design. Term: 15 years.

The patent bargain & why IP = company valuation

A patent is a bargain with the public: you share the invention with the public (full disclosure) in exchange for 20-year exclusivity. The lecture stresses IP "creates an intangible asset that is worth real financial valuation" — for a biotech, the patent portfolio is the valuation.

What each IP right actually lets the owner DO

The card's "5 main IP rights" table lists the term and requirement for each right, but omits the source's "KEY DIFFERENCES" column on what the owner is actually empowered to do. The lecture's grid states:

Concrete examples of protectable subject matter

The card describes each right abstractly. The lecture's KEY DIFFERENCES grid gives concrete examples of what falls under each category — useful for the "identify the IP in this product" exercises:

The paper-clip exercise — prior art vs the new design

Core exercise: draft a claim that covers the new design but does NOT cover the prior art, assuming no other prior art.

• Prior art = the trombone design: a long, elongated U-shaped loop of wire.
• Invention = concentric circular loops: a first circular loop with a second circular loop inside it, sharing a centre.
• Distinguishing features: continuous wire · first circular loop · second circular loop · second loop inside the first · concentric.

The invention is the shape; material, alloy ratio, weight and dimensions are decoration that only costs scope.

Claim 1 for the exercise — structure only

Source wording: A paper clip comprising: a continuous wire formed into a first circular loop and a second circular loop, wherein the second loop is disposed within the first loop and is concentric with the first loop.

No material, no ratio, no weight, no dimensions, no comparison with the prior art — only absolute structure. That is broad enough to cover every working version of the design, yet it still clears the trombone, whose loop is neither circular nor concentric.

Independent vs dependent claims — the ladder and the fallback

The independent claim (Claim 1) must be as broad as possible; the dependent claims add limitations and act as fallback positions. The source's claim set:

Anyone inside Claim 1 infringes, including a competitor using a completely different material: avoiding Claim 3's material or Claim 5's ratio does not escape Claim 1. And if Claim 1 is later attacked by prior art, the dependent claims are positions to retreat to — the source names Claim 4, the alloy ratio, as that fallback position.

The source states the practice sequence outright: Claim 1 structural → Claim 2 material → Claim 3 weight → Claim 4 dimensions.

Why NOT to put a material ratio in Claim 1

A ratio can be claimed — the question is where. In the independent claim it does damage: only a clip made of that alloy infringes, so anyone using stainless steel, plastic or a different copper alloy escapes, and the protection scope narrows immediately. The source's reason is blunt — the invention point was the structure, not the material.

Why "not heavier than the prior art" is bad claim drafting

1. "Lighter than the prior art" is a relative term — the boundary is not clear.
2. Claims should be defined by absolute structure or absolute numerical values.
3. Weight is a result, not a structure.
4. The examiner may therefore object that the claim is indefinite / lacks clarity.

• ❌ "not heavier than a conventional paper clip" → relative to the prior art; unclear boundary.
• ⚠️ "a mass less than 0.5 grams" → absolute, so clearer, but very narrow.
• ✅ "so that the paper clip uses less metal than a trombone-style paper clip" → still functional / relative; best left to the specification.

Weight also depends on dimensions and material: if the concentric-loop structure already uses less metal, the saving may be inherent, and a weight limitation alone may fail to distinguish small prior art.

When the material ratio IS the invention point

1. Define it precisely — not "different ratios", but wt%, at% and explicit ranges. A ratio without numerical boundaries is indefinite.
2. Avoid overlapping components. Bronze is itself a copper–tin alloy, so "bronze, copper and iron" is unclear. Write the elemental composition instead: "an alloy consisting essentially of copper, tin, and iron, wherein the alloy comprises 70–90 wt% Cu, 5–20 wt% Sn, and 1–10 wt% Fe" — with coherent percentages.
3. Support it with experimental data: the specification must show why the ratio is good, why it is lighter than the prior art, and whether the strength is adequate (enablement and written description).
4. File a separate alloy claim plus an article claim — one to the alloy, one to "a paper clip made from the alloy of claim X" — protecting both the material and the product made from it.

From paper clips to drugs — same logic at molecular scale

The tutorial generalises the exercise to pharmaceutical patents. The principle is unchanged — broad independent claim, narrow dependent claims, structure first, effects in the specification — but the dimension being claimed changes:

• Structure: macroscopic, visible, mechanical → molecular, invisible, chemical / biological.
• Ratio: material ratio → molar ratio, weight ratio, synergistic ratio.
• Size: physical dimensions → molecular weight, degree of polymerisation, sequence length.
• Predictability: high → low (the unpredictable arts).
• Sufficient disclosure: easy → hard (needs data, deposits, sequence listings).
• Claim types: one product type → product, composition, method, use.
• Infringement test: structure comparison → structure, sequence, function, equivalents.

The rule survives the translation: do not put "ratio 1:3" or "molecular weight 150 kDa" into Claim 1 — that narrows scope exactly as a material ratio narrows the paper-clip claim.

Claim-type checklist for drugs

Where the paper clip has essentially one claim type, a drug has five. Ask of each: where do the structure, the ratio and the size go?

• Compound — the molecule itself: "A compound of Formula I, or a pharmaceutically acceptable salt thereof." Structure is the substance of the claim (Markush substituents, a specific compound, salt, crystalline form, stereoisomer); size as a molecular-weight range or sequence.
• Composition — compound plus carrier: "A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient." Ratio is at home here, e.g. a weight ratio of 1:1 to 1:10.
• Formulation — dosage or physical form. Ratio again (co-crystal molar ratio; polymer–drug conjugate molar ratio 1:2 to 1:5) and size (particle size of 10 nm to 100 nm).
• Method — "A method of treating disease Y, comprising administering the compound of claim 1." Structure recited through the compound; dose and ratio may appear as limitations. Jurisdiction-sensitive.
• Use — the compound for a stated therapeutic use. Structure recited; the use distinguishes. The route taken where a direct method claim is unavailable.

The source's small-molecule ladder: Claim 1 the broad compound genus → Claim 2 a substituent definition (R1 is C1–C6 alkyl) → Claim 3 a specific compound → Claim 4 a composition → Claim 5 that composition's weight ratio → Claim 6 a method of treatment.

Molecular size claims — why "just a different size" usually fails

• Molecular-weight range — "…wherein the polymer has a molecular weight of 5,000 to 50,000 Da."
• PEGylation — "…wherein the protein is conjugated to PEG having a molecular weight of 20 kDa."
• Antibody fragment — "…wherein the antibody is a Fab fragment having a molecular weight of about 50 kDa."
• Nucleic acid length — "…wherein the nucleic acid has 15 to 30 nucleotides."

Biotech doctrines that change the drafting

Six biotech rules sit on top of the paper-clip logic (developed further in the L2 card):

• Markush claims — a very large class of compounds claimed together, but the class must share a common structure.
• Genus vs species — Claim 1 is the genus (the class); Claim 2 is a species (one member of it).
• Sufficiency / enablement — the skilled person must be able to make the whole claimed range, not just one example.
• Biological deposits — cells, strains and hybridomas that cannot be described in words must be deposited.
• Sequence listings — nucleic acids and proteins are identified by submitted sequence listings.
• Unpredictable arts — a small change can have a large effect; this helps non-obviousness but makes sufficiency harder.

The four-step test — and what is NOT patentable

For any change of ratio, structure or size, all four steps must be satisfied:

1. Novel — not disclosed by a single piece of prior art.
2. Inventive — not an obvious variant.
3. Sufficiently described — the specification supports the claim.
4. Unexpected effect — the new ratio / structure / size delivers a surprising result.

Steps 1–3 are the ordinary requirements; step 4 is what actually earns patentability in an unpredictable art, and so what must be built into the data before filing. The excluded categories mirror it — each is a change a skilled person would have made anyway: routine optimisation of a known compound; simple substitution of a known group; routine ratio adjustment with no unexpected effect; a size change with no functional difference.

Worked examples and combination therapy

The source also flags a jurisdiction constraint: China and Europe restrict methods of treatment. A combination-therapy invention that could be a method claim in the US must therefore be drafted as a composition claim or as a pharmaceutical-use claim — the "use in the manufacture of a medicament" style:

• Combination as a composition: "A combination comprising compound A and compound B in a synergistic ratio."
• Synergy carried in a dependent claim: "The composition of claim 1, wherein the composition exhibits a synergistic effect."
• Ratio kept out of Claim 1: Claim 1 recites the two compounds; the weight ratio "1:1 to 1:10" sits in a dependent claim.